Johnson & Johnson & Services, Inc.’s Janssen Pharmaceutical Company to announce its acquisition of U.S. FDA approval for IMBRUVIGA (ibrutinib). IMBRUVIGA is a BTKi treatment for pediatric patients with chronic graft-versus-host disease (cGVHD) after the failure of systemic therapy.
Zimmer Biomet Holdings, Inc. announces its three-year agreement with Hospital for special surgery (HSS). The agreement is established to make HSS/Zimmer Biomet (ZB) Innovation Center for Artificial Intelligence (AI).
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 773
Published Date: Feb 09, 2023
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
Increasing sales of orthopedic devices and rising cases of osteoporosis across the globe are estimated to majorly boost the market growth.
The market is anticipated to attain a CAGR of 6% over the forecast period, i.e., 2023-2033.
The lack of skilled medical professionals and requisite technology is estimated to challenge the market growth.
The market in North America region is projected to hold the largest market share by the end of 2033 and provide more business opportunities in the future.
The major players in the market are Wright Medical Group N.V., Zimmer Biomet Holdings, Inc., Arthrex, Inc., Medical Device Business Services, Inc., Johnson & Johnson & Services, Inc., RTI Surgical, Inc., MTG Learning Media Pvt. Ltd., and others.
The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue-generating capacity as well as the new products being launched into the market by the company.
The market is segmented by solution, application, end-user, and by region.
The hospitals segment is anticipated to garner the largest market size by the end of 2033 and display significant growth opportunities.